Drug news

NICE recommends Revlimid for specific Myelodysplastic syndromes - Celgene

Read time: 1 mins

Last updated:20th Aug 2014

Published:20th Aug 2014

Source: Pharmawand

In new final draft guidance, the National Institute for Health and Care Excellence (NICE) has recommended use of Revlimid (lenalidomide) from Celgene in a specific type of Myelodysplastic syndromes (MDS) that is characterised by a chromosomal abnormality called an isolated deletion 5q cytogenetic abnormality. Currently, the main treatment option for people with this kind of MDS is best supportive care including regular blood transfusions.

Learning Zone Homepage

Albumin in fluid management Learning Zone

Explore expert-led content discussing guidelines for fluid management, clinical trial data and emerging uses of albumin in this Learning Zone.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Ojemda (tovorafenib) receives FDA accelerated approval for relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG), the most common form of childhood brain tumor

Day One Biopharmaceuticals, Inc , announced that the FDA has approved Ojemda (tovorafenib), a type II RAF inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory BRAF-altered pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation

4 mins

Drug news

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria.

Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase II/III CALINA study, demonstrating that a novel formulation of Coartem (artemether-lumefantrine) developed for babies weighing less than 5kg with malaria has the required pharmacokinetic profile and good efficacy and safety

3 min

Drug news

European Commission approves Emblaveo (aztreonam-avibactam) for patients with multidrug-resistant infections and limited treatment options

Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for Emblaveo (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis

1 min

See all news